A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.
Head and Neck Squamous Cell Carcinoma|Lung Cancer|Oesophageal Cancer
DRUG: Durvalumab|DRUG: Tremelimumab|RADIATION: SBRT
Dose Limiting Toxicity (DLT), Event possibly related to study drugs and fulfills any one of the following criteria using CTCAE Version 4.03, Approximately 8 weeks
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.